Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.38 Average PT from Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, six have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $56.3750.

Several analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Zacks Research raised Immunocore from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 5th. Morgan Stanley set a $43.00 price target on shares of Immunocore in a report on Friday, August 7th. Finally, TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research report on Monday, August 24th.

Immunocore Trading Up 0.5%

NASDAQ IMCR opened at $37.57 on Friday. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -101.54 and a beta of 0.74. Immunocore has a 52 week low of $27.56 and a 52 week high of $40.71. The business has a 50 day moving average price of $34.39 and a 200-day moving average price of $31.72. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. As a group, equities analysts expect that Immunocore will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunocore

Several institutional investors have recently modified their holdings of the business. Harbour Investments Inc. lifted its holdings in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares during the period. R Squared Ltd grew its stake in Immunocore by 7.4% in the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after purchasing an additional 606 shares during the period. Leonteq Securities AG bought a new position in Immunocore in the 4th quarter valued at $30,000. Orion Porfolio Solutions LLC increased its position in shares of Immunocore by 4.5% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock valued at $752,000 after purchasing an additional 1,031 shares during the last quarter. Finally, Arax Advisory Partners increased its position in shares of Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after purchasing an additional 1,042 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.